US › Healthcare

Gyre Therapeutics Inc. (GYRE)

US · Healthcare · Biotechnology

$6.15+0.65%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$22.5M
Revenue YoY
+2.1%
Net profit
$-8.6M
Profit YoY
-419.3%
EPS
$-0.10
EPS estimate
$-0.07
Net margin
-38.3%

EPS came in at -0.10 against a street estimate of -0.07 — a miss of 42.9%.

Key statistics

Market cap
$641.1M
Forward P/E
78.1
P/B
6.33
Book value
$1.11
EPS (TTM)
$-0.08
52-week high
$9.42
52-week low
$5.44
50-day MA
$6.18
200-day MA
$7.31
Beta
4.78

Analyst view

Analysts rate Gyre Therapeutics Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $18.67.

Shareholding

Insiders
86.33%
Institutions
3.77%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC0.88%
BlackRock Inc0.68%
Geode Capital Management, LLC0.39%
State Street Corp0.19%
SBI Securities Co Ltd0.15%
Charles Schwab Investment Management Inc0.15%
Vanguard Fiduciary Trust Co0.12%
Northern Trust Corp0.12%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Gyre Therapeutics Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.